Compare GLP-1 Drugs: Every Drug Side by Side in One Table

All 10 FDA-approved GLP-1 medicines side by side: what each is approved for, trial weight loss, the most common side effect and the monthly price. Then pick a head-to-head below.

Medicines: 10
Manufacturers: Novo Nordisk, Eli Lilly and others

Compare GLP-1 drugs: GLP-1 pens, pills and a vial side by side

Weight loss and half-life at a glance

How long each drug stays in your body

Half-life in days: how long your body needs to get rid of half a dose. Section 12.3 of each FDA label gives the number.

The weight lost in the main weight trial for each medicine

Percentage of body weight. Trials, doses and lengths differ, so compare each result with the placebo from the same study on that drug's page.

Sources (10)

FDA labels (DailyMed) 1 2 3 4 5 6 7 8 9 10.

Daily pill

Wegovy pill

semaglutide · Novo Nordisk

What it costs: $149a month⁵; Paying cash, the lowest self-pay monthly price is at NovoCare for the pill, 1.5 mg.
Trial weight loss: 13.6%²²; of body weight. Trial OASIS 4, 64 weeks; placebo at 2.4%.

Half-life of the drugabout 1 week²²
Main side effectLike the pen, mostly nausea²²

Self-pay $149
TrumpRx $149
Insured from $25
Medicare $50
List $1,349.02

Daily pill

Rybelsus

semaglutide · Novo Nordisk

What it costs: $149a month¹; Cash payment: the lowest self-pay price per month (NovoCare, Ozempic pill, which replaces Rybelsus).
Trial weight loss: 3.7 kg²³; Weight lost over 26 weeks in PIONEER 1 (type 2 diabetes); placebo -1.4 kg.

Half-life of the drugabout 1 week²³
Main side effect
Nausea 20% at 14 mg, placebo 6%²³

Self-pay $149
Insured from $25
List $1,027.51

Daily pill

Foundayo

orforglipron · Eli Lilly

What it costs: $149a month¹⁵; Paying cash through LillyDirect, 0.8 mg or 2.5 mg gives you the lowest self-pay price each month.
Trial weight loss: 11.1%²⁴; ATTAIN-1, 72 weeks, measured a loss of body weight. Placebo: 2.1%.

Half-life of the drug29 to 49 hours²⁴
Main side effect
At 17.2 mg, nausea was 35%, compared with 10% for placebo²⁴

Self-pay $149
Insured from $25
Medicare $50
List $649

Weekly pen

Ozempic

semaglutide · Novo Nordisk

What it costs: $199a month¹; Cash payment, the lowest self-pay rate per month (NovoCare, first 2 fills of the pen intro, 0.25 mg and 0.5 mg).
Trial weight loss: 4.7 kg²⁵; in SUSTAIN 1 over 30 weeks, with type 2 diabetes, this weight was lost; placebo -1.2 kg.

Half-life of the drugabout 1 week²⁵
Main side effect
At 1 mg, nausea was 20.3%, compared with 6.1% for placebo²⁵

Self-pay $199
TrumpRx $199
Insured from $25
List $1,027.51

Weekly pen

Wegovy pen

semaglutide · Novo Nordisk

What it costs: $199a month⁴; Cash payment, the lowest self-pay rate per month (NovoCare, first 2 fills of the pen intro, 0.25 mg and 0.5 mg).
Trial weight loss: 14.9%²²; STEP 1, 68 weeks, measured a loss of body weight. Placebo: 2.4%.

Half-life of the drugabout 1 week²²
Main side effect
At 2.4 mg, nausea was 44%, compared with 16% for placebo²²

Self-pay $199
TrumpRx $199
Insured from $25
Medicare $50
List $1,349.02

Weekly pen or vial

Zepbound

tirzepatide · Eli Lilly

What it costs: $299a month¹²; Paying cash, the lowest self-pay price a month (LillyDirect, a vial or the KwikPen 2.5 mg).
Trial weight loss: 20.9%²⁶; SURMOUNT-1, 72 weeks, measured a loss of body weight. Placebo: 3.1%.

Half-life of the drug5 to 6 days²⁶
Main side effect
Nausea 29% at 10 mg, versus placebo 8%²⁶

Self-pay $299
TrumpRx $299
Insured from $25
Medicare $50
List $499 to $1,086

Daily pen

Victoza

liraglutide · Novo Nordisk

What it costs: $543.51a month²⁰; The monthly list price, before any discount.
Trial weight loss: 2.5 kg²⁷; lost in LEAD-3, over 52 weeks in type 2 diabetes; glimepiride +1.1 kg.

Half-life of the drugabout 13 hours²⁷
Main side effect
Nausea in 20% at 1.8 mg, placebo 5%²⁷

List $543.51

Weekly pen

Trulicity

dulaglutide · Eli Lilly

What it costs: $1,006.93a month¹⁹; The monthly list price, before any discount.
Trial weight loss: 4.6 kg²⁸; lost in AWARD-11, 36 weeks in type 2 diabetes, Dulaglutide 4.5 mg weekly.

Half-life of the drugabout 5 days²⁹
Main side effect
Nausea: 21.1% at 1.5 mg, placebo 5.3%²⁹

Insured from $25
List $1,006.93

Weekly pen

Mounjaro

tirzepatide · Eli Lilly

What it costs: $1,112.16a month¹¹; The monthly list price, before any discount.
Trial weight loss: 7.8 kg³⁰; type 2 diabetes, SURPASS-1, 40 weeks: weight lost, placebo -1.0 kg.

Half-life of the drugabout 5 days³⁰
Main side effect
Nausea: 18% at 15 mg, placebo 4%³⁰

Insured from $25
Not covered $499
Medicare $0 to $50
List $1,112.16

Daily pen

Saxenda

liraglutide · Novo Nordisk

What it costs: $1,349.02a month²¹; The monthly list price, before any discount.
Trial weight loss: 7.4%³¹; SCALE Obesity and Prediabetes, 56 weeks: body weight lost. Placebo: 3%.

Half-life of the drugabout 13 hours³¹
Main side effect
Nausea 39.3%³¹ Saxenda, placebo 13.8%

List $1,349.02

Complete comparison table

All FDA-approved GLP-1 drugs sold in the US, with the lowest self-pay price listed first
Medicine	Form	FDA-approved for	Weight loss in trials	Most common side effect	Price a month
Wegovy pill semaglutide, Novo Nordisk	Daily pill	Weight loss, Heart risk, MASH liver disease	OASIS 4, 64 weeks: 13.6% of body weight, placebo 2.4%²²	Like the pen, mostly nausea²²	Self-pay $149 NovoCare, pill 1.5 mg⁵ Other ways to pay Pill, starting dose: TrumpRx $149 a month² Insurance: from $25 with a savings card, and your plan must cover it⁵ Weight loss use: Medicare $50, through the GLP-1 Bridge⁶ List $1,349.02 per month⁷
Rybelsus semaglutide, Novo Nordisk	Daily pill	Type 2 diabetes, Heart risk	PIONEER 1, type 2 diabetes, 26 weeks: 3.7 kg lost, placebo -1.4 kg²³	Nausea 20% 14 mg, placebo 6%²³	Self-pay $149 NovoCare, Ozempic pill, which replaces Rybelsus¹ Other ways to pay Insurance: from $25 with a savings card, and your plan must cover it⁸ List $1,027.51 per 30 tablets⁹
Foundayo orforglipron, Eli Lilly	Daily pill	Weight loss	in ATTAIN-1, 72 weeks, 11.1% of body weight against 2.1% on placebo²⁴	Nausea 35% 17.2 mg, placebo 10%²⁴	Self-pay $149 LillyDirect, 0.8 mg and 2.5 mg¹⁵ Other ways to pay Insurance: from $25 with a savings card, and your plan must cover it¹⁶ Weight loss use: Medicare $50, through the GLP-1 Bridge¹⁶ List $649 per month¹⁷
Ozempic semaglutide, Novo Nordisk	Weekly pen	Kidney disease in type 2 diabetes, along with Type 2 diabetes and Heart risk	in SUSTAIN 1, for type 2 diabetes over 30 weeks, 4.7 kg lost versus -1.2 kg on placebo²⁵	Nausea 20.3% 1 mg, placebo 6.1%²⁵	Self-pay $199 NovoCare, pen intro (first 2 fills, 0.25 mg and 0.5 mg)¹ Other ways to pay For the pen starting dose, TrumpRx $199 a month² Insurance: from $25 with a savings card, and your plan must cover it¹ List $1,027.51 per pen³
Wegovy pen semaglutide, Novo Nordisk	Weekly pen	Weight loss, Heart risk, MASH liver disease	in STEP 1, 68 weeks, 14.9% of body weight versus 2.4% on placebo²²	Nausea 44% 2.4 mg, placebo 16%²²	Self-pay $199 NovoCare, pen intro (first 2 fills, 0.25 mg and 0.5 mg)⁴ Other ways to pay For the pen starting dose, TrumpRx $199 a month² Insurance: from $25 with a savings card, and your plan must cover it⁵ Weight loss use: Medicare $50, through the GLP-1 Bridge⁶ List $1,349.02 per month⁷
Zepbound tirzepatide, Eli Lilly	Weekly pen or vial	Weight loss, Sleep apnea	in SURMOUNT-1, 72 weeks, 20.9% of body weight versus 3.1% on placebo²⁶	Nausea 29% 10 mg, placebo 8%²⁶	Self-pay $299 LillyDirect, vial or KwikPen 2.5 mg¹² Other ways to pay For the vial starting dose, TrumpRx $299 a month² Insurance: from $25 with a savings card, and your plan must cover it¹³ Weight loss use: Medicare $50, through the GLP-1 Bridge¹³ Per fill, the listed price is $499 to $1,086¹⁴
Victoza liraglutide, Novo Nordisk	Daily pen	Type 2 diabetes, Heart risk	in LEAD-3, for type 2 diabetes over 52 weeks, 2.5 kg lost, while glimepiride gave +1.1 kg²⁷	Nausea 20% 1.8 mg, placebo 5%²⁷	List $543.51 per 2 pens²⁰
Trulicity dulaglutide, Eli Lilly	Weekly pen	Type 2 diabetes, Heart risk	in AWARD-11, for type 2 diabetes over 36 weeks, 4.6 kg lost while taking Dulaglutide 4.5 mg each week²⁸	Nausea 21.1% 1.5 mg, placebo 5.3%²⁹	List $1,006.93 per fill¹⁹ Other ways to pay Insurance: from $25 with a savings card, and your plan must cover it¹⁸
Mounjaro tirzepatide, Eli Lilly	Weekly pen	Type 2 diabetes, Heart risk	in SURPASS-1, for type 2 diabetes over 40 weeks, 7.8 kg lost versus -1.0 kg on placebo in the trial³⁰	Nausea 18% 15 mg, placebo 4%³⁰	List $1,112.16 per fill¹¹ Other ways to pay Insurance: from $25 with a savings card, and your plan must cover it¹⁰ $499 savings card when your plan does not cover it¹⁰ About 8 in 10 people pay $0 to $50 through Medicare Part D¹⁰
Saxenda liraglutide, Novo Nordisk	Daily pen	Weight loss	in SCALE Obesity and Prediabetes, 56 weeks, 7.4% of body weight versus 3% on placebo³¹	Nausea 39.3% Saxenda, placebo 13.8%³¹	List $1,349.02 per 5 pens²¹

Sources (31)

¹²³⁴⁵⁶⁷⁸⁹¹⁰¹¹¹²¹³¹⁴¹⁵¹⁶¹⁷¹⁸¹⁹²⁰²¹, FDA label on DailyMed 1 2 3 4 5 6 7 8 9, PubMed.

Big trial weight loss results

GLP-1 trial results
Trial	Who	Length	Average weight loss by arm	Placebo	Source
STEP 1	Adults with obesity or overweight, without diabetes	68 weeks	Semaglutide 2.4 mg weekly 14.9%	2.4%	FDA label (DailyMed)
OASIS 4	Adults with obesity or overweight, without diabetes	64 weeks	Wegovy pill 25 mg daily 13.6%	2.4%	FDA label (DailyMed)
SURMOUNT-1	Adults with obesity or overweight, without diabetes	72 weeks	15% Tirzepatide 5 mg weekly; 19.5% Tirzepatide 10 mg weekly; 20.9% Tirzepatide 15 mg weekly	3.1%	FDA label (DailyMed)
SURMOUNT-2	Adults who have obesity or overweight plus type 2 diabetes	72 weeks	12.8% Tirzepatide 10 mg weekly; 14.7% Tirzepatide 15 mg weekly	3.2%	PubMed
SURMOUNT-5	Adults with obesity, without type 2 diabetes	72 weeks	Zepbound: Tirzepatide 10 or 15 mg each week, 20.2%; Wegovy: Semaglutide 1.7 or 2.4 mg each week, 13.7%	Not listed	PubMed
SCALE Obesity and Prediabetes	Adults with obesity or overweight who do not have type 2 diabetes	56 weeks	Liraglutide 3.0 mg daily 7.4%	3%	FDA label (DailyMed)
ATTAIN-1	Adults with obesity or overweight, without diabetes	72 weeks	7.4% Foundayo 5.5 mg daily; 8.3% Foundayo 9 mg daily; 11.1% Foundayo 17.2 mg daily	2.1%	FDA label (DailyMed)
ATTAIN-2	Adults who have obesity or overweight plus type 2 diabetes	72 weeks	5.1% Foundayo 5.5 mg daily; 7% Foundayo 9 mg daily; 9.6% Foundayo 17.2 mg daily	2.5%	FDA label (DailyMed)
STEP 2	Adults who have obesity or overweight plus type 2 diabetes	68 weeks	Semaglutide 2.4 mg weekly 9.6%	3.4%	PubMed
STEP-HFpEF	Adults with obesity and heart failure with preserved ejection fraction	52 weeks	Semaglutide 2.4 mg weekly 13.3%	2.6%	PubMed

Compare GLP-1 Drugs: Every Drug Side by Side in One Table

Weight loss and half-life at a glance

Wegovy pill

Rybelsus

Foundayo

Ozempic

Wegovy pen

Zepbound

Victoza

Trulicity

Mounjaro

Saxenda

Complete comparison table

Sources

Big trial weight loss results

Head-to-heads people read most

All compare pages

All GLP-1 medicines

Ozempic

Saxenda

Tirzepatide

Zepbound

Wegovy

Mounjaro

Rybelsus

Semaglutide

Foundayo

Orforglipron

Trulicity

Weight loss and half-life at a glance

Complete comparison table

Sources

Big trial weight loss results

Head-to-heads people read most

Ways to compare

All compare pages

All GLP-1 medicines

Ozempic

Saxenda

Tirzepatide

Zepbound

Wegovy

Mounjaro

Rybelsus

Semaglutide

Foundayo

Orforglipron

Trulicity